

Sarborg Curates Veterinary Disease Database to Expand AI Signature Intelligence Platform into Animal Health

WILMINGTON, De – May 12, 2026 -- Sarborg Limited (“**Sarborg**” or the “**Company**”), today announced the curation of the Sarborg Veterinary Disease Database, a proprietary collection of veterinary disease signatures that significantly expands the Company’s AI Signature Agent platform into the global animal health market.

The Veterinary Disease Database comprises more than 120 disease signatures across a range of species including cattle, pig, dog, sheep and chicken. Each disease signature enables immediate computational analysis within Sarborg’s Signature Agent architecture.

A defining feature of the database is its cross-species interoperability, facilitating direct comparison with human-derived drug and disease signatures. This creates a translational bridge between animal and human biology, unlocking both veterinary-specific opportunities and clinically relevant animal models.

The dataset spans infectious disease, oncology, cardiovascular, neurological, dermatological, reproductive and metabolic conditions. The database enables rapid identification of therapeutic overlaps, repurposing opportunities and combination strategies across species.

This expansion represents a significant strategic move into a large and underexplored market. Animal health remains structurally under-analysed from a systems biology perspective. Sarborg’s platform introduces a scalable, data-driven approach to opportunity identification, positioning the Company to generate differentiated intellectual property and commercial pathways within veterinary medicine.

This release further expands Sarborg’s growing ecosystem of proprietary datasets, including the Sarborg 1,600 Disease Database, the Sarborg 1,700 Rare Disease Database, the Sarborg 1,600 Bacteria Database, the Sarborg 4,500 Agrichemical Database and additional datasets in development. The continued expansion of these datasets strengthens the Company’s ability to systematically identify and execute on high-value opportunities.

The Veterinary Disease Database will be deployed across Sarborg’s internal programs and select external collaborations. It also provides a strong foundation for identifying high-quality animal models to support translational research and downstream development.

Following the Company’s acquisition of Manoira’s cannabinoid solid-form asset portfolio for \$65m, Sarborg has begun applying its platform to veterinary health use cases. Manoira retains a license for veterinary applications, and the parties are working together to utilise the Veterinary Disease Database and Signature Agent platform to identify new indications and development opportunities within animal health.

Sarborg is actively engaging with pharmaceutical, animal health and biotechnology organisations seeking to leverage signature-based approaches within veterinary and translational research programs.

“The Veterinary Disease Database represents a major step forward for our platform and a clear point of differentiation,” said Mark Taylor, Director of Sarborg. “We are now able to analyse veterinary and human biology within a unified framework, identify opportunities across both domains and generate actionable outputs in a fraction of the time required by traditional approaches. This opens up a significant new market for Sarborg.”

About Sarborg Limited

Sarborg is an agentic AI signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures, Sarborg's agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:

info@sarborg.com

www.sarborg.com